Carisbamate in Adult & Pediatric Subjects With Lennox-Gastaut Syndrome

Lennox Gastaut Syndrome Clinical Trial

Official title:

Phase I, Open-Label, Pharmacokinetic, Dose Escalation Study of Carisbamate in Adult and Pediatric Subjects With Lennox-Gastaut Syndrome

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03731715
• Other study ID #: YKP509C001
• Status: Completed
• Phase: Phase 1
• Start date: February 7, 2019
• Est. completion date: June 29, 2022

Study information

• Verified date: May 2023
• Source: SK Life Science, Inc.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is an open-label, multi-center study of carisbamate in adult and pediatric subjects with LGS, with single- and multiple-dose PK assessments from Days 1 through 73. There will be a Screening Period of up to 28 days and a Treatment Period of 87 days.

Description:

A total of 24 subjects are planned: 6 subjects in each of 4 cohorts: Cohort I (≥18 years), Cohort II (12 to <18 years), Cohort III (6 to <12 years), and Cohort IV (2 to <6 years). For Cohorts I and II, PK assessments of carisbamate, S-enantiomer and its R-enantiomer plasma concentrations, will be conducted on Days 1, 2 and 3 of the single dose period at pre-dose and 0.5, 1, 1.5, 2, 4, 6, 8, 12, 24, and 48 hours after dosing and on Day 17 of the multiple-dose period at pre dose and 0.5, 1, 1.5, 2, 4, 6, 8, and 12 hours after dosing; trough samples will be collected on Days 45 and 73 of the dose-adjustment period. For Cohort III, PK assessments of carisbamate, S-enantiomer and its R-enantiomer plasma concentrations will be conducted on Days 1, 2 and 3 of the single dose period at pre dose and 0.5, 1, 2, 4, 6, 8, 12, 24, and 48 hours after dosing and on Day 17 of the multiple-dose period at pre-dose and 2 hours after dosing; trough samples will be collected on Days 45 and 73 of the dose-adjustment period. For Cohort IV, a sparse PK sampling approach will be used, and the time of PK sampling time will be based on the PK results from the other cohorts. A maximum of 2 to 4 time points on each day (1 and 17) will be collected. Safety assessments include adverse event (AE) and concomitant medication reporting, clinical laboratory testing, vital sign measurements, 12 lead electrocardiograms (ECGs), physical examinations, and neurologic examinations.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 18
• Est. completion date: June 29, 2022
• Est. primary completion date: May 23, 2022
• Accepts healthy volunteers: No
• Gender: All
• Age group: 2 Years and older

Eligibility

Inclusion Criteria:

1. Diagnosis of LGS as evidenced by the following:

1. More than 1 type of generalized seizure, including drop seizures (atonic, tonic, or myoclonic), for =6 months before Visit 1

2. Previous electroencephalogram reporting diagnostic criteria for LGS (abnormal background activity accompanied by slow spike-and-wave pattern <2.5 Hz)

2. Male or female aged =2 years at the time of consent

3. Aged <11 years at the onset of LGS

4. Written informed consent signed by the subject or legal guardian prior to entering the study in accordance with the ICH GCP guidelines. Age appropriate assent will be obtained for children and adolescents. If the written informed consent is provided by the legal guardian because the subject is unable to do so, a written or verbal assent from the subject must also be obtained.

5. Receiving 1 to 3 concomitant AEDs at a stable dose for =30 days before Visit 1 (vagal nerve stimulation [VNS] and ketogenic diet, stable and ongoing for =30 days before Visit 1, do not count as AEDs)

6. In the Investigator's opinion, parents or caregivers must be able to report accurate seizure assessments during the screening and study periods and subjects must be able to ingest study drug

7. Body weight =8 kg for subjects enrolled in Cohort IV

8. Subjects with an implanted vagal nerve stimulator will be allowed if the vagal nerve stimulator was implanted at least 5 months prior to Visit 1 (Screening) and the stimulator parameters are not changed for 30 days prior to Visit 1 and for the duration of the study

9. Subjects following a ketogenic diet will be allowed as long as the diet has been stable for at least 30 days prior to Visit 1 (Screening) and will remain stable for the duration of the study.

Exclusion Criteria:

1. Progressive neurological disease

2. Prior treatment with carisbamate

3. Evidence of clinically significant disease or any medical condition that would compromise the subject's ability to safely complete the study

4. Any surgical or medical condition that may interfere with the absorption, distribution, metabolism, or excretion of the investigational medicine product

5. Acute disease state (e.g., nausea, vomiting, fever, or diarrhea) within 7 days before Day 1

6. Scheduled for surgery during the study

7. Ketogenic diet or VNS, unless stable and ongoing for =30 days before Visit 1

8. Treatment with an investigational drug or device =30 days before Visit 1

9. Status epilepticus within 12 weeks of Visit 1

10. Felbamate for <1 year (subjects taking felbamate for =1 year must have a stable dose for 60 days before Visit 1)

11. Concomitant use of vigabatrin or other medications known to be inducers of CYP3A

12. Use of drugs known as UGT inducers, e.g., carbamazepine, phenytoin, phenobarbital, primidone, or oxcarbazepine

13. Use of cannabinoids (any form), cannabidiols, or medical or recreational marijuana

14. Use of any prescription or non-prescription drugs, including over-the-counter medication, non-routine vitamins and herbal products within 2 weeks prior to study drug administration unless discussed and agreed with the Sponsor's medical representative in writing. (Medication used to treat TEAEs does not lead to a compulsory exclusion of subjects.)

15. Consumption of any caffeine-containing products (e.g., coffee, tea, chocolate, or soda) or alcoholic beverages within 48 hours before Day 1 and until the end of each PK sampling period

16. Consumption of grapefruit or grapefruit-containing products within 72 hours before Day 1 and until the end of each PK sampling period

17. History of any serious drug-induced hypersensitivity reaction (including but not limited to Stevens Johnson syndrome, toxic epidermal necrolysis, Drug Rash with Eosinophilia and Systemic Symptoms [DRESS]) or any drug-related rash requiring hospitalization

18. History of AED-associated rash that involved conjunctiva or mucosae

19. History of more than one non-serious drug-related hypersensitivity reaction that required discontinuation of the medication

20. Significant clinical laboratory abnormalities, including elevation of serum AST or ALT more than 1.5 times ULN for age group, or any elevation of bilirubin or creatinine about the ULN for age group at Screening

21. Any clinically-significant uncontrolled medical illness, including hepatic or renal failure, ischemic disease, human immunodeficiency virus (HIV) infection, active sexually-transmitted disease (STD), active viral hepatitis, malignancy, or any disorder that in the judgement of the investigator places the subject at risk by participation in this study

22. History of drug-induced liver injury

23. Positive urine screen of drugs of abuse (if not due to concomitant medication, e.g. benzodiazepines as hypnotics) for adult and adolescent subjects.

24. Adrenocorticotropic hormone within the 6 months before Visit 1

25. History of anoxic episodes requiring resuscitation within 6 months before Visit 1, drug or alcohol dependency or abuse within approximately the last 2 years, or use of illegal recreational drugs

26. Females who are breastfeeding or pregnant at Screening or Baseline or who are of reproductive age and do not agree to be abstinent or to use highly effective contraception

27. Intermittent use of benzodiazepine of >4 single administrations in the month before Visit 1

28. Clinically significant abnormality on the 12-lead ECG at Screening, and any child or adolescent with a QTcF less than 330 ms or greater than 450 ms

29. Congenital short QT syndrome

30. Hypersensitivity to the study drug or any of the excipients

31. Psychotic disorder(s) or unstable recurrent affective disorder(s)

Related Conditions & MeSH terms

• Lennox Gastaut Syndrome
• Syndrome

Intervention

Drug:
• Carisbamate
An oral liquid formulation (20 mg/mL) of carisbamate (S-carisbamate)

Locations

Country	Name	City	State
United States	Johns Hopkins Hospital	Baltimore	Maryland
United States	Duke Health	Durham	North Carolina
United States	Dartmouth-Hitchcock Medical Center	Lebanon	New Hampshire
United States	Hospital of the University of Pennsylvania	Philadelphia	Pennsylvania
United States	Oregon Health and Science University	Portland	Oregon
United States	UW Valley Medical Center	Renton	Washington
United States	The University of Utah School of Medicine - Primary Children's Hospital (Primary Children's Medical Center)	Salt Lake City	Utah

Sponsors (1)

Lead Sponsor	Collaborator
SK Life Science, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	The area under the curve (AUC) of carisbamate after a single and multiple doses of carisbamate.	Safety Assessment	Days 1-3, Day 17
Primary	The maximum plasma concentration (Cmax) after a single and multiple doses of carisbamate.	Safety assessment	Days 1-3, Day 17
Secondary	Safety - adverse events (AEs) reporting after a single and multiple doses of carisbamate.	Adverse event assessment for seriousness (yes, no), severity (mild, moderate, severe), affect on carisbamate dosing (increase, reduced, interrupted, withdrawn, no change), and outcome (recovered/resolved,recovered/resolved with sequelae, recovering/resolving, not recovered/not resolved, fatal or unknown).	Days 1-87